The KARISMA study: Breast cancer prevention and breast density

A study published last week in the Journal of the National Cancer Institute reported on the results of the KARISMA trial. The trial results showed promise for (Z)-endoxifen, a tamoxifen metabolite, as an alternative to the popular tamoxifen treatment (but with fewer side effects) due to its ability to reduce breast density. A reduction in breast density during treatment has been found to improve clinical outcomes.

Why breast density matters

Mammographic breast density (MBD) refers to the proportion of dense fibroglandular tissue visible on a mammogram relative to overall breast tissue. It’s a meaningful risk marker as women with high breast density face a significantly elevated risk of developing breast cancer, and dense tissue can also obscure tumors during screening, making early detection harder. Reducing MBD, then, isn’t simply a cosmetic metric. It functions as a proxy for lowered cancer risk: less dense tissue suggests the hormonal environment driving tumor growth is being suppressed.

What the KARISMA trial found

This is where the endoxifen data becomes genuinely compelling, and worth any patient or caregiver adding to their endoxifen guide when discussing options with their oncology team.

In the KARISMA-Endoxifen trial, researchers tested low oral doses of (Z)-endoxifen directly, bypassing the metabolic variability that complicates tamoxifen therapy. The results showed that even modest doses produced meaningful reductions in breast density:

Dose	Drug	Breast density reduction
1 mg/day	(Z)-Endoxifen	19.3%
2 mg/day	(Z)-Endoxifen	26.5%
20 mg/day	Tamoxifen	~18.5% (typical)

A daily 1 mg dose of (Z)-endoxifen reduced MBD by 19.3%, while a 2 mg dose achieved a 26.5% reduction, surpassing the approximately 18.5% reduction typically seen with a standard 20 mg tamoxifen dose.

A lower dose and stronger signal

That last comparison deserves a second look. A dose that is ten times smaller is outperforming the current standard of care on a clinically relevant endpoint. What’s driving this? Directness. Rather than relying on each patient’s liver to convert tamoxifen into its active form, (Z)-endoxifen delivers the therapeutic agent immediately, without the metabolic guesswork.

This matters beyond prevention. As research continues to validate endoxifen’s efficacy at low doses in hormone-sensitive tissue, scientists are now exploring whether that same potency translates to patients facing a far more urgent challenge: metastatic breast cancer.

Endoxifen in metastatic breast cancer

The conversation around endoxifen has largely centered on prevention and early-stage hormone receptor-positive (HR+) breast cancer. But emerging clinical data suggests its role may extend much further, offering real promise for patients facing metastatic disease.

When researchers shifted focus toward advanced settings, the endoxifen vs. tamoxifen comparison produced results that were difficult to ignore.

Key Finding: According to a “Study May Proceed” letter from the FDA, Atossa Therapeutics said that (Z)-endoxifen more than doubled the median progression-free survival compared to tamoxifen (7.4 months versus 2.4 months) among patients who had not received CDK4/6 inhibitors (considered standard of care in advanced HR+ breast cancer). For this group, endoxifen represents a potentially potent frontline endocrine option before cycling through additional treatment lines.

Here’s why this matters for the broader landscape of metastatic care:

• Endocrine-sensitive tumors respond strongly. Patients whose cancers remain sensitive to estrogen suppression are precisely the population most likely to benefit from a more potent, consistent endocrine agent like (Z)-endoxifen.
• Progression-free survival is a meaningful marker. Longer PFS translates directly to more time before disease worsening, which is critically important for patients managing metastatic disease.
• Treatment sequencing implications are significant. Preserving CDK4/6 inhibitor options while achieving strong disease control with endoxifen could reshape how oncologists approach first-line endocrine therapy decisions.

Of course, these results are preliminary, and larger confirmatory trials are needed before endoxifen becomes a routine recommendation in metastatic settings. That said, the data is compelling enough to warrant serious attention.

What this emerging evidence doesn’t yet fully address, and what deserves its own close look, is how patients actually tolerate this therapy over time.

Tolerability and side effects: Why low dose matters

For many women, the hardest part of hormone therapy isn’t the diagnosis, it’s staying on treatment. Research shows that a significant number of patients discontinue tamoxifen early due to side effects that erode daily quality of life. Hot flashes, night sweats, mood changes, joint pain, and sexual dysfunction aren’t minor inconveniences; they’re the kinds of disruptions that make women quietly stop filling their prescriptions.

This is where endoxifen’s potency becomes a real-world advantage, not just a pharmacological one.

Because (Z)-endoxifen is the active driver of tamoxifen’s therapeutic effect, it can be dosed at significantly lower quantities while still producing meaningful clinical results. Less drug volume in the body often translates directly to fewer and less severe side effects. In the KARISMA trial, the 1 mg dose demonstrated meaningful breast density reduction, a validated marker of treatment response, while appearing to sidestep many of the adverse effects that derail standard tamoxifen therapy.

Dr. Steven Quay, CEO of the National Cancer Institute, put it plainly:

“The potential that 1 mg of [Z]-endoxifen may significantly reduce breast density… potentially without many of the intolerable [adverse] effects, is extremely encouraging.”

Here’s how the side effect profiles compare at a glance:

Common tamoxifen side effects patients report:

• Hot flashes and night sweats
• Vaginal dryness or discharge
• Mood changes and depression
• Joint and muscle pain
• Fatigue
• Increased blood clot risk

Low-dose endoxifendoxifen’s emerging tolerability profile:

• Reduced frequency of vasomotor symptoms
• Lower systemic drug burden overall
• Fewer reports of intolerable adverse effects in early trials

Staying on treatment is only possible when treatment is livable. Endoxifen’s low-dose profile suggests it could be the option that finally bridges that gap and knowing how to access it is the next critical step.

Accessing the future: Clinical trials and next steps

Endoxifen isn’t yet available as a standard prescription — but that’s changing fast. (Z)-endoxifen clinical trials are actively underway, with Phase 2 and Phase 3 studies are evaluating its role in both breast density reduction and metastatic treatment. For patients who want access today, enrolling in a trial may be the most direct path.

You can search for current studies at ClinicalTrials.gov, which lists active endoxifen studies for estrogen receptor-positive breast cancer, or through the Outcomes4Me Clinical Trial Finder.

Questions to ask your oncologist

• Am I a candidate for endoxifen based on my HR+ diagnosis?
• Have I been tested for CYP2D6 genetic variants that affect tamoxifen metabolism?
• Are there active endoxifen trials I qualify for near me?
• How does my current treatment compare to precision medicine approaches?

Current trial status: Phase 2 and Phase 3 (Z)-endoxifen clinical trials are ongoing across multiple institutions, making now the right time to ask your care team where you stand.